Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Tappenden

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
International Journal of Technology Assessment in Health Care|January 17, 2023
A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UKPaul Tappenden, Aline Navega Biz, Mónica Hernández Alava, et al.
Pharmacoeconomics|August 11, 2016
Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Sue Harnan, Shijie Ren, et al.
Health Technology Assessment (Winchester, England)|July 30, 2015
A systematic review and economic evaluation of exercise referral schemes in primary care: a short reportFiona Campbell, Mike Holmes, Emma Everson-Hock, et al.
Multiple Sclerosis and Related Disorders|July 31, 2020
Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of AmericaRichard K Burt, Paul Tappenden, Xiaoqiang Han, et al.
Health Technology Assessment (Winchester, England)|October 21, 2015
Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreathSue E Harnan, Paul Tappenden, Munira Essat, et al.
Pharmacoeconomics|November 17, 2016
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Health Technology Assessment (Winchester, England)|April 7, 2016
The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysisEva Kaltenthaler, Christopher Carroll, Daniel Hill-McManus, et al.
The Journal of Infection|October 19, 2010
Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic reviewRachel J Jackson, Katy L Cooper, Paul Tappenden, et al.
Pharmacoeconomics|March 13, 2017
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Pharmacoeconomics - Open|February 15, 2018
Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal ProcessEva Kaltenthaler, Christopher Carroll, Daniel Hill-McManus, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
International Journal of Technology Assessment in Health Care|January 17, 2023
A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UKPaul Tappenden, Aline Navega Biz, Mónica Hernández Alava, et al.
Pharmacoeconomics|August 11, 2016
Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Sue Harnan, Shijie Ren, et al.
Health Technology Assessment (Winchester, England)|July 30, 2015
A systematic review and economic evaluation of exercise referral schemes in primary care: a short reportFiona Campbell, Mike Holmes, Emma Everson-Hock, et al.
Multiple Sclerosis and Related Disorders|July 31, 2020
Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of AmericaRichard K Burt, Paul Tappenden, Xiaoqiang Han, et al.
Health Technology Assessment (Winchester, England)|October 21, 2015
Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreathSue E Harnan, Paul Tappenden, Munira Essat, et al.
Pharmacoeconomics|November 17, 2016
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Health Technology Assessment (Winchester, England)|April 7, 2016
The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysisEva Kaltenthaler, Christopher Carroll, Daniel Hill-McManus, et al.
The Journal of Infection|October 19, 2010
Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic reviewRachel J Jackson, Katy L Cooper, Paul Tappenden, et al.
Pharmacoeconomics|March 13, 2017
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Pharmacoeconomics - Open|February 15, 2018
Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal ProcessEva Kaltenthaler, Christopher Carroll, Daniel Hill-McManus, et al.
Pageof 9